These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30600607)

  • 41. A Comparison of the Quality of Informed Consent for Clinical Trials of an Experimental Hookworm Vaccine Conducted in Developed and Developing Countries.
    Diemert DJ; Lobato L; Styczynski A; Zumer M; Soares A; Gazzinelli MF
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005327. PubMed ID: 28114401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Audio-visual presentation of information for informed consent for participation in clinical trials.
    Ryan RE; Prictor MJ; McLaughlin KJ; Hill SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003717. PubMed ID: 18254029
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patient and Provider Perspectives Regarding Enrollment in Head and Neck Cancer Research.
    Shuman AG; Gornick MC; Brummel C; Kent M; Spector-Bagdady K; Biddle E; Bradford CR; Brenner JC
    Otolaryngol Head Neck Surg; 2020 Jan; 162(1):73-78. PubMed ID: 31818193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. "As Long as You Ask": A Qualitative Study of Biobanking Consent-Oncology Patients' and Health Care Professionals' Attitudes, Motivations, and Experiences-the B-PPAE Study.
    Yip S; Fleming J; Shepherd HL; Walczak A; Clark J; Butow P
    Oncologist; 2019 Jun; 24(6):844-856. PubMed ID: 30413662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Additional germline findings from a tumor profiling program.
    Stjepanovic N; Stockley TL; Bedard PL; McCuaig JM; Aronson M; Holter S; Semotiuk K; Leighl NB; Jang R; Krzyzanowska MK; Oza AM; Gupta A; Elser C; Ahmed L; Wang L; Kamel-Reid S; Siu LL; Kim RH
    BMC Med Genomics; 2018 Aug; 11(1):65. PubMed ID: 30092803
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient understanding of, satisfaction with, and perceived utility of whole-genome sequencing: findings from the MedSeq Project.
    Roberts JS; Robinson JO; Diamond PM; Bharadwaj A; Christensen KD; Lee KB; Green RC; McGuire AL;
    Genet Med; 2018 Sep; 20(9):1069-1076. PubMed ID: 29300387
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Motivations, concerns and preferences of personal genome sequencing research participants: Baseline findings from the HealthSeq project.
    Sanderson SC; Linderman MD; Suckiel SA; Diaz GA; Zinberg RE; Ferryman K; Wasserstein M; Kasarskis A; Schadt EE
    Eur J Hum Genet; 2016 Jan; 24(1):14-20. PubMed ID: 26036856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
    Mandelker D; Donoghue M; Talukdar S; Bandlamudi C; Srinivasan P; Vivek M; Jezdic S; Hanson H; Snape K; Kulkarni A; Hawkes L; Douillard JY; Wallace SE; Rial-Sebbag E; Meric-Bersntam F; George A; Chubb D; Loveday C; Ladanyi M; Berger MF; Taylor BS; Turnbull C
    Ann Oncol; 2019 Aug; 30(8):1221-1231. PubMed ID: 31050713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. When "no" might not quite mean "no"; the importance of informed and meaningful non-consent: results from a survey of individuals refusing participation in a health-related research project.
    Williams B; Irvine L; McGinnis AR; McMurdo ME; Crombie IK
    BMC Health Serv Res; 2007 Apr; 7():59. PubMed ID: 17462081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered.
    Bijlsma RM; Bredenoord AL; Gadellaa-Hooijdonk CG; Lolkema MP; Sleijfer S; Voest EE; Ausems MG; Steeghs N
    Eur J Hum Genet; 2016 Oct; 24(10):1496-500. PubMed ID: 27071717
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expectations and experiences of patients with cancer participating in phase I clinical trials.
    Yoder LH; O'Rourke TJ; Etnyre A; Spears DT; Brown TD
    Oncol Nurs Forum; 1997 Jun; 24(5):891-6. PubMed ID: 9201741
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overcoming challenges to meaningful informed consent for whole genome sequencing in pediatric cancer research.
    Oberg JA; Glade Bender JL; Cohn EG; Morris M; Ruiz J; Chung WK; Appelbaum PS; Kung AL; Levine JM
    Pediatr Blood Cancer; 2015 Aug; 62(8):1374-80. PubMed ID: 25832998
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Perceptions of cancer patients and their physicians involved in phase I trials.
    Daugherty C; Ratain MJ; Grochowski E; Stocking C; Kodish E; Mick R; Siegler M
    J Clin Oncol; 1995 May; 13(5):1062-72. PubMed ID: 7738612
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Informed consent in clinical practice: patients' experiences and perspectives following surgery.
    Ochieng J; Buwembo W; Munabi I; Ibingira C; Kiryowa H; Nzarubara G; Mwaka E
    BMC Res Notes; 2015 Dec; 8():765. PubMed ID: 26653100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor genome analysis includes germline genome: are we ready for surprises?
    Catenacci DV; Amico AL; Nielsen SM; Geynisman DM; Rambo B; Carey GB; Gulden C; Fackenthal J; Marsh RD; Kindler HL; Olopade OI
    Int J Cancer; 2015 Apr; 136(7):1559-67. PubMed ID: 25123297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.
    Langenberg KPS; Meister MT; Bakhuizen JJ; Boer JM; van Eijkelenburg NKA; Hulleman E; Ilan U; Looze EJ; Dierselhuis MP; van der Lugt J; Breunis W; Schild LG; Ober K; van Hooff SR; Scheijde-Vermeulen MA; Hiemcke-Jiwa LS; Flucke UE; Kranendonk MEG; Wesseling P; Sonneveld E; Punt S; Boltjes A; van Dijk F; Verwiel ETP; Volckmann R; Hehir-Kwa JY; Kester LA; Koudijs MMJ; Waanders E; Holstege FCP; Vormoor HJ; Hoving EW; van Noesel MM; Pieters R; Kool M; Stumpf M; Blattner-Johnson M; Balasubramanian GP; Van Tilburg CM; Jones BC; Jones DTW; Witt O; Pfister SM; Jongmans MCJ; Kuiper RP; de Krijger RR; Wijnen MHW; den Boer ML; Zwaan CM; Kemmeren P; Koster J; Tops BBJ; Goemans BF; Molenaar JJ
    Eur J Cancer; 2022 Nov; 175():311-325. PubMed ID: 36182817
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implementing precision cancer medicine in the genomic era.
    Chen HZ; Bonneville R; Roychowdhury S
    Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of patient and surgeon preoperative expectations of spinal surgery.
    Lattig F; Fekete TF; OʼRiordan D; Kleinstück FS; Jeszenszky D; Porchet F; Mutter U; Mannion AF
    Spine (Phila Pa 1976); 2013 May; 38(12):1040-8. PubMed ID: 22825477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.